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INTRODUCTION
Vitamin D is a liposoluble steroid hormone 
formed by cyclopentane perhydro-phenanthrene 
















is the active form that is synthesized in 





(20). The organs involved in vitamin D synthesis are 
skin, liver and kidney (18). Vitamin D synthesis be-
gins in the skin where UVB brakes down C9-C10 
bond of the precursor 7-dehydrocholesterol produc-
ABSTRACT
Vitamin D is an essential steroid hormone. The role of Vitamin D in mineral metabolism and skeletal health 
as related to calcium homeostasis is well established. In addition to this role, vitamin D has been recently 
accepted also as immune modulator and thus it could be possibly implicated in the pathogenesis of system-
ic lupus erythematosus (SLE). This review focuses on the question: „Is vitamin D deficiency involved in the 
pathogenesis of SLE or is it a consequence of the disease state?” and comments the known positive effects of 
vitamin D supplementation on SLE disease activity.
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ing cholecalciferol. Cholecalciferol is transported to 
the liver and submitted to hydroxylation by 25-hy-
droxylase enzyme, forming 25-hydroxycholecalcif-
erol (25(OH)D
3
). The final phase of the biosynthesis 
is in kidney where the enzyme 1-alpha-hydroxylase 





. Vitamin D is also obtained from 





), for example cod liver oil, fishes, eggs, 
mushrooms, etc.









equal to 1:1000. 
The classical role of Vitamin D is assumed to be its ef-
fect on mineral metabolism and skeletal health as re-
lated to calcium homeostasis. The regulation of calci-
um uptake is due to the absorption at intestinal, bone 
and kidney levels (29). Recent studies discovered that 
calcitriol played an important role in what is called 
non-classical vitamin D functions that included cell 
apoptosis/anti-proliferation, providing anticancer 
effects and immunomodulation (21). The non-clas-
sical vitamin D functions are mediated by the vita-





 binds with VDR and the 
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-VDR with retinoid X recep-
tor (RXRs) binds to the VDRE response elements on 
DNA changing the activity of different genes respon-
sible for immunomodulation and regulation of vari-
ous immunemediated processes (27).
In the current review, we aim to describe the 
immune modulatory effects of vitamin D, risk fac-
tors for vitamin D deficiency in patients with system-
ic lupus erythematosus (SLE), role of deficiency in 
pathogenesis of SLE, and potential positive effects of 
vitamin D supplementation on SLE disease activity.
VITAMIN D IMMUNE MODULATORY 
EFFECTS
The identification that the dendritic cells, which 
have central role to the maintenance of self-tolerance, 





 and respond to this through the 
VDR in autocrine way suggests that vitamin D is an 
immune modulator (17,25,43). VDRs are found also 
in monocytes, macrophages and activated T and B 
cells and these cells also may convert vitamin D into 
its active form (45). 
Vitamin D as immune modulator decreases 
Th1 CD4+ T cells and reduces the expression of IL-
2, IFN-γ, TNF-α,IL-12, IL-6 and IL-17 (23,36,30); in-
creases the production of IL-4, IL-5, and IL-10, lead-
ing to the development of a Th2 T-cell population (11, 
30); increases the number and function of regulato-
ry T cells (Treg) (51); inhibits Th17 cells important 
in the development of autoimmunity (23,36); inhib-
its monocyte differentiation into dendritic cells and 
blocks the stimulatory effects of T cells on them (8, 
40); enhances monocyte differentiation into mac-
rophages, but reduces their capacity to present anti-
gens to lymphocytes by decreasing the expression of 
MHC-II molecule (15,31); prevents the proliferation 
of activated B cells and immunoglobulin production 
(26,46); induces apoptosis in activated B cells (16,55); 
inhibits posts switch memory B cells (16,45,55); in-
hibits production of IFN-γ from natural killer (NK) 
and T cells (60) (Figure 1). 





ment of the innate immune responses, while main-
taining self-tolerance by inhibiting the adaptive im-
mune responses. Over recent years it has been dem-
onstrated that deficiency of 25(OH)D
3
 is related to 
increasing risk of autoimmune diseases such as in-
sulin-dependent diabetes mellitus (IDDM), multiple 
sclerosis (MS), inflammatory bowel disease (IBD), 
rheumatoid arthritis (RA), and systemic lupus ery-
thematosus (SLE) (36).
SYSTEMIC LUPUS ERYTHEMATOSUS AC-
TIVITY AND VITAMIN D LEVELS
SLE is multiorgan autoimmune disease, more 
prevalent in African-Americans than in Caucasians, 
typically involving women in childbearing age (13). 
SLE is characterize by the loss of tolerance to nuclear 
antigens, immune complexes (ICs) depositions in tis-
sues, delayed clearance of apoptotic cells and inflam-
matory cytokine release. 
In many cohort studies, involving a large num-
ber of participants, low serum concentrations of 
25(OH)D
3
 correlated with SLE disease activity, as-
sessed by SLEDAI (systemic lupus erythemato-
sus disease activity index) and BILAG (British Isles 
Lupus Assessment Group) (3,6,7,10,12,19,24,35,38, 
39,44,51,56,57,58,59). High titres of anti-double 
stranded (ds) DNA, anti-C1q antibodies and low se-
rum levels of C3 and C4 complement are also use-
ful tools to monitor SLE disease activity in prac-
tice. Also, significant inverse association between vi-
tamin D levels and anti-dsDNA antibodies and di-
rect association between vitamin D and complement 
C3 and C4 levels were established in several studies 
(9,10,35,37,51).
This significant inverse relation between vita-
min D content and the determined SLE disease ac-
tivity set   an open question: Is vitamin D deficiency 
Figure 1. Vitamin D effects on the innate and adaptive 
immune response
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involved in the pathogenesis of SLE or is it a conse-
quence of the disease state? On one side, for SLE pa-




1. One of most common disease manifestations 
is skin photosensitivity. Patients with SLE 
have to avoid sun exposure because of trig-
gering of lupus f lare. The result in blocking 
UVB-induced synthesis of cholecalciferol in 
the skin. It is known that people with dark-
er skin pigmentation who are living far from 
the equator are especially prone to vitamin D 
deficiency, due to the protection of melanin 
from harmful UVB light. This could explain, 
in part, the vitamin D deficiency among Af-
rican-Americans (25). It is no coincidence 
that this ethnic group has a higher risk for de-
velopment of SLE and SLE is characterized by 
the most severe disease manifestations. 
2. Chronic treatment of SLE patients with corti-
costeroids and anticonvulsants may alter the 
vitamin D metabolism, may reduce vitamin 
D-binding protein levels or downregulate the 
function of VDR (36,58). 
3. Renal involvement in SLE patients with lupus 
nephritis may affect the hydroxylation step of 
25(OH)D
3 
in the kidneys (47).
On the other side, immune modulatory effects 
of vitamin D suggest possible major specific role in 
SLE pathogenesis. Ritterhouse et al. (2011) found ev-
idences in this aspect, observing that vitamin D de-
ficiency in healthy individuals was associated with 
an increased presence of antinuclear antibodies an-
tibodies (ANA) (45). This finding is interesting, be-
cause it demonstrates the relation between vitamin 
D deficiency and the immune response in the ab-
sence of any other risk factors for vitamin D defi-
ciency, typical for SLE patients, and suggests that vi-
tamin D deficiency in autoimmunity is not solely a 
consequence of the disease. Also the fact that both 
healthy individuals and patients with SLE, positive 
for ANA, have decreased vitamin D suggests that vi-
tamin D deficiency is involved in the early stages of 
SLE pathogenesis. Most studies have found a reduc-
tion in Treg cells in lupus patients in steroid thera-
py (14).
The role of vitamin D deficiency in the patho-
genesis of SLE is also shown in other studies of Rit-
terhouse et al. (2011) – vitamin D deficiency is asso-
ciated with significant hyperactivation of B cells, au-
toantibody production and IFN-α activity in SLE pa-
tients (45). IFN-α is one of the key cytokines in the 
pathogenesis of SLE. Association between raised 
IFN-α levels and increased disease activity in SLE is 
known fact. The complement system plays a major 
and complex role in the SLE, because it may prevent 
and also exacerbate the disease. Sakem et al. (2003) 
found that low levels of 25(OH)D
3
 were directly re-
lated to the levels of IgG2 and complement compo-
nent C4. In contrast these low levels of 25(OH)D
3
 
were reversely associated with the levels of IgG1 and 
IgA and complement component C3 (49). This shows 
that vitamin D insufficiency may lead to a poor im-
mune response. Interestingly Linker-Israeli et. al. 
(2001) found increased numbers of T, B and NK cells 
expressing the VDR in SLE patients compared to 
healthy controls. This suggests that in SLE the im-
mune system may have increased sensitivity to vita-
min D (33).
VITAMIN D STATUS AND METHODS FOR 
ANALYSIS
According to The Institute of Medicine (IOM) 
and the Endocrine Society’s Clinical Guidelines (22). 
Evaluation treatment and prevention of vitamin D 
deficiency, the optimum values for 25(OH)D3 are at 
less or higher than 30 ng/ml because it is suggested 
that the maximum effect of vitamin D on calcium 
metabolism and bone health are in the interval be-
tween 30-40 ng/ml. Concentrations between 21-29 
ng/ml are related to vitamin D insufficiency and val-
ues lower than 20 ng/ml (50 nmol/l) are considered 
vitamin D deficient because at this concentrations of 
25(OH)D
3
 parathormone (PTH) starts increasing.
The most important methods to determine the 
concentration of 25(OH)D
3
 are immunoassays and 
chromatographic technics. Immunoassay methods 
are based on using a monoclonal antibody to 25(OH)
D
3
 with a colour product formation proportion-
al to its concentration (enzyme-immunoassay, che-
miluminiscence) or using RIA method. Chromato-
graphic methods (HLPC, LC-MS/MS), are separa-
tive technics that isolate and quantify the 25(OH)D
3
 
using mass-spectrometry. The advantages of immu-
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noassay methods are that they have relatively short 
technological time, they are easy to manage and are 




ic technics are referential methods with a high preci-
sion and accuracy, where the matrix cannot change 
the final results. However, they are very expensive, 
require long technological time and appropriate spe-
cific devices. Most studies reporting vitamin D levels 
use immunoassay methods that are not so accurate 
and precise as compared to chromatographic ones. 
This may be the cause for statistical errors and prob-
ably may explain why there are research groups that 
have not found an association between SLE disease 
activity and vitamin D status (28,34,47,48,50,53,54).
VITAMIN D SUPPLEMENTATION IN SLE 
PATIENTS
An interesting question, which is yet to be an-
swered, is whether supplementation with vitamin D 
alters the course and prognosis of SLE. Intervention-
al studies give contradictory results for the clinical 
outcomes. Three clinical studies showed no signifi-
cant correlations between vitamin D supplementa-
tion and SLE disease activity (4,5,48). Other recent 
studies have found that supplementation with vita-
min D is associated: with a decrease in disease ac-
tivity (32,41) and in proteinuria (41); with an im-
provement in inflammatory and hemostatic param-
eters (1); with an increase in Treg cells and a reduc-
tion in Th1 and Th17 cells in a time dependent man-
ner (11,42,52); with an inhibition of B cell prolifera-
tion, induction of apoptosis and reduced differentia-
tion into plasma cells (16); with a decrease in memory 
B cells and in anti-DNA antibodies (52).
Despite established potential beneficial effects 
of vitamin D in SLE, to date, vitamin D supplementa-
tion is not the standard of care for patients with SLE 
because there is no consensus about recommend-
ed targeted vitamin D serum levels and the optimal 
mode and dose of vitamin D supplementation (23). 
Randomized, controlled trials are needed to evalu-
ate the type, dose, duration and any side effects of the 
vitamin D supplementation needed to achieve phar-
macological and clinical efficacy.
CONCLUSION
There are unresolved questions which answers 
will enucleate better the causal connection between 
the levels of vitamin D and the pathogenesis of SLE: 
Which is the most appropriate phase of SLE to assess 
vitamin D levels (at the time of diagnosis or in remis-
sion)?; What is the cut off value of “normal” versus 
“insufficient” and “deficient” vitamin D levels in SLE 
patients?; What are the minimal beneficial levels of 
vitamin D in the management of SLE?; What should 
be the dose and duration of vitamin D supplementa-
tion?; How important are the intake of other medica-
tions, age, gender, geographic location, ethnicity, sun 
protective behaviour and genetic variations for the 
metabolism of vitamin D in SLE patients?
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